Constellation’s CSO and Scientific Advisor Receive Medal of Honor from American Cancer Society
Company’s Scientific Leaders Recognized for Outstanding Contributions in Cancer Research-
CAMBRIDGE, MA – November 23, 2009 – Constellation Pharmaceuticals, Inc., today announced that the American Cancer Society has awarded the Medal of Honor to Edward E. Harlow, Jr., Ph.D., the company’s Chief Scientific Officer, and Arnold J. Levine, Ph.D., a member of the company’s Scientific Advisory Board. This award from the American Cancer Society, the nation’s leading voluntary health organization and largest non-governmental investor in cancer research, represents the Society’s highest honor in recognition of outstanding contributions to fighting cancer.
Dr. Harlow was awarded the Society’s Medal of Honor for Basic Research in recognition of his discoveries regarding the control of cell division and critical changes that allow cancer to develop, in particular for insights regarding how viruses induce tumors and the role of the p53 protein. He recently joined Constellation’s leadership team as Chief Scientific Officer from his prior role at Harvard Medical School where he served as Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology and Associate Director of the Dana-Farber/Harvard Cancer Center. Previously he served as Scientific Director for the Massachusetts General Hospital Cancer Center and as Associate Director for Science Policy at the National Cancer Institute, where he helped direct U.S. cancer research planning. Dr. Harlow has received numerous scientific honors, including election to the National Academy of Sciences and the Institute of Medicine, appointment as Fellow of the American Academy of Arts and Sciences, and many others.
Dr. Levine, who is Professor in the School of Natural Sciences at the Institute for Advanced Study in Princeton, New Jersey, and Professor of Pediatrics and Biochemistry at The Cancer Institute of New Jersey, also received the Society’s Medal of Honor for Basic Research. Dr. Levine is one of the leading scientists credited with the discovery of p53 as a tumor suppressor, and his research provided a new paradigm regarding the pathogenesis of cancer. He has been a member of Constellation’s Scientific Advisory Board since the founding of the company. Dr. Levine is a member of the National Academy of Sciences and the Institute of Medicine, and has received numerous awards, including the Lila Gruber Cancer Research Award, the Josef Steiner Prize, the Bristol-Meyers Squibb Award for Distinguished Achievements in Cancer Research, the Paul Ehrlich and Ludwig Darmstaeder Prize, among others.
"We at Constellation congratulate Drs. Harlow and Levine for receiving this honor from the American Cancer Society in recognition of the tremendous contributions these scientists have made to the field of cancer biology through the course of their highly productive careers," said Mark A. Goldsmith, M.D., Ph.D., Chief Executive Officer of Constellation Pharmaceuticals. "A fundamental value at Constellation is leading-edge scientific thinking, which comes from an intellectual collaboration among our talented staff, scientific founders, advisors and Chief Scientific Officer. We believe that the combination of high-quality discovery science and drug discovery will translate into important new drugs for patients based on the epigenetics."
About Constellation Pharmaceuticals Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science that focuses on selective regulators of gene function and expression. Constellation’s initial focus is in oncology, and the Company’s platform will also be applicable to other therapeutic areas including autoimmune, inflammatory and neurological diseases. The Company’s academic founders represent the core thought leaders in epigenetics responsible for key advances, insights and discoveries in the field. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company’s website at constpharma.wpengine.com.
Constellation Pharmaceuticals was founded by three of the foremost authorities and leaders within the field of Epigenetics: Danny Reinberg, Ph.D, Professor of Biochemistry at the New York University School of Medicine and an Investigator of the Howard Hughes Institute; Yang Shi, Ph.D., Professor of Pathology at the Harvard Medical School and David Allis, Ph.D., Professor and Head of the Laboratory of Chromatin Biology at The Rockefeller University.
Constellation’s Board of Directors include: Anthony Evnin, Partner, Venrock; David Goeddel, Ph.D., Partner, The Column Group; Mark Levin, Partner, Third Rock Ventures; Tom Maniatis, Ph.D., Professor, Harvard University; Robert Tepper, M.D., Partner, Third Rock Ventures; and Mark A. Goldsmith, M.D., Ph.D., CEO, Constellation Pharmaceuticals.
Also supporting the Company’s efforts is a Scientific Advisory Board featuring some of the most renowned scientific experts within the field of Epigenetics and oncology, including; Richard Klausner, M.D., Managing Partner, The Column Group and former Director of the National Cancer Institute; Arnold Levine, Ph.D., Professor, Institute of Advanced Study; David Livingston, M.D., Deputy Director, Dana Farber/Harvard Cancer Institute; Julian Adams, Ph.D., Chief Scientific Officer, Infinity Pharmaceuticals; Xiaodong Cheng, Ph.D., Professor, Emory University; Thomas Jenuwein, Ph.D., Director, Max Planck Institute; and Scott Lowe, Ph.D., Professor, Cold Spring Harbor Laboratory.
About Epigenetics Epigenetics is an exciting new field of biology that involves chemical modifications of both DNA and of its packaging proteins (“chromatin"), which are collectively called the ‘epigenome.’ The genome, or DNA, is the “blueprint" for the human body, consisting of thousands of genes, which are the fundamental units of information necessary for normal cell growth and development. In contrast, the epigenome plays a critical role in regulating the expression of genes, that is, switching genes on or off – or in the case of disease, for switching genes on or off incorrectly. This new field of Epigenetic science provides the opportunity to create a broad new class of human therapeutics targeting selective regulators of epigenetic function.
Contact: Barbara Yates Yates Public Relations 781-258-6153